Does the media refer more to MOLN or ALT?

In the previous week, Altimmune had 2 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Altimmune and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.00 beat Altimmune's score of -0.07 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MOLN or VALN?

In the previous week, Molecular Partners had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for Valneva. Valneva's average media sentiment score of 0.27 beat Molecular Partners' score of 0.00 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valneva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTMX or MOLN?

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 2 articles in the media. CytomX Therapeutics' average media sentiment score of 0.62 beat Molecular Partners' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STTK or MOLN more profitable?

Shattuck Labs' return on equity of -43.57% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Molecular Partners N/A -68.36% -54.82%

Does the media prefer STTK or MOLN?

In the previous week, Shattuck Labs and Shattuck Labs both had 2 articles in the media. Shattuck Labs' average media sentiment score of 0.00 equaled Molecular Partners'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALLO or MOLN more profitable?

Allogene Therapeutics' return on equity of -50.04% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -50.04% -36.74% Molecular Partners N/A -68.36% -54.82%

Does the media prefer ALLO or MOLN?

In the previous week, Molecular Partners had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 equaled Molecular Partners'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Molecular Partners (MOLN) Competitors

$4.30 +0.04 (+0.94%)

Closing price 09/23/2026 03:08 PM Eastern

Extended Trading

$4.04 -0.26 (-6.14%)

As of 04:12 AM Eastern

Compare

MOLN vs. ALT, VALN, CTMX, STTK, and ALLO

Should you buy Molecular Partners stock or one of its competitors? Molecular Partners's main competitors and comparable companies include Altimmune (ALT), Valneva (VALN), CytomX Therapeutics (CTMX), Shattuck Labs (STTK), and Allogene Therapeutics (ALLO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Molecular Partners compare to Altimmune?

Molecular Partners (NASDAQ:MOLN) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Molecular Partners has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-68.36%	-54.82%
Altimmune	-214,860.98%	-31.41%	-26.96%

Molecular Partners has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Molecular Partners currently has a consensus target price of $8.38, suggesting a potential upside of 94.77%. Altimmune has a consensus target price of $14.33, suggesting a potential upside of 349.32%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Molecular Partners has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	30.73	-$74.41M	-$1.71	N/A
Altimmune	$31K	20,016.53	-$88.09M	-$0.78	N/A

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Altimmune had 2 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Altimmune and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.00 beat Altimmune's score of -0.07 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Altimmune beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Valneva?

Molecular Partners (NASDAQ:MOLN) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Molecular Partners has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Valneva has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Molecular Partners has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	30.73	-$74.41M	-$1.71	N/A
Valneva	$197.56M	3.05	-$130.33M	-$2.11	N/A

In the previous week, Molecular Partners had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for Valneva. Valneva's average media sentiment score of 0.27 beat Molecular Partners' score of 0.00 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Molecular Partners has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Molecular Partners' return on equity of -68.36% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-68.36%	-54.82%
Valneva	-110.33%	-153.20%	-39.50%

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Molecular Partners currently has a consensus target price of $8.38, indicating a potential upside of 94.77%. Valneva has a consensus target price of $9.30, indicating a potential upside of 46.46%. Given Molecular Partners' stronger consensus rating and higher probable upside, research analysts clearly believe Molecular Partners is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Molecular Partners beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Molecular Partners has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Molecular Partners	N/A	-68.36%	-54.82%

CytomX Therapeutics has higher revenue and earnings than Molecular Partners. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.95	-$17.37M	-$0.50	N/A
Molecular Partners	$5.65M	30.73	-$74.41M	-$1.71	N/A

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CytomX Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

CytomX Therapeutics presently has a consensus target price of $11.90, indicating a potential upside of 328.06%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 94.77%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CytomX Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 2 articles in the media. CytomX Therapeutics' average media sentiment score of 0.62 beat Molecular Partners' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CytomX Therapeutics beats Molecular Partners on 12 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Shattuck Labs and Shattuck Labs both had 2 articles in the media. Shattuck Labs' average media sentiment score of 0.00 equaled Molecular Partners'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Shattuck Labs has higher earnings, but lower revenue than Molecular Partners. Shattuck Labs is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	638.31	-$48.81M	-$0.51	N/A
Molecular Partners	$5.65M	30.73	-$74.41M	-$1.71	N/A

Shattuck Labs' return on equity of -43.57% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Molecular Partners	N/A	-68.36%	-54.82%

Shattuck Labs currently has a consensus price target of $12.78, suggesting a potential upside of 100.91%. Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 94.77%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe Shattuck Labs is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Shattuck Labs beats Molecular Partners on 11 of the 13 factors compared between the two stocks.

How does Molecular Partners compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Allogene Therapeutics currently has a consensus price target of $8.30, indicating a potential upside of 397.01%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 94.77%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Allogene Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Allogene Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

In the previous week, Molecular Partners had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.00 equaled Molecular Partners'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Molecular Partners has higher revenue and earnings than Allogene Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$4.64M	124.35	-$190.89M	-$0.67	N/A
Molecular Partners	$5.65M	30.73	-$74.41M	-$1.71	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Allogene Therapeutics' return on equity of -50.04% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Molecular Partners	N/A	-68.36%	-54.82%

Summary

Allogene Therapeutics beats Molecular Partners on 11 of the 15 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$172M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-2.51	13.88	274.07	25.69
Price / Sales	30.73	1,356.95	643.13	79.17
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.79	15.40	10.47	6.32
Net Income	-$74.41M	-$22.82M	$3.49B	$359.73M
7 Day Performance	4.75%	-1.71%	-0.67%	0.17%
1 Month Performance	-2.27%	-6.18%	-3.17%	-3.27%
1 Year Performance	16.82%	30.64%	15.13%	5.58%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	1.847 of 5 stars	$4.30 +0.9%	$8.38 +94.8%	+14.5%	$172M	$5.65M	N/A	134
ALT Altimmune	2.2417 of 5 stars	$3.24 +0.3%	$14.33 +342.4%	-15.8%	$630.25M	$40K	N/A	57	News Coverage Positive News Analyst Forecast
VALN Valneva	1.7558 of 5 stars	$6.57 +0.3%	$9.30 +41.6%	-36.7%	$623.43M	$197.56M	N/A	674
CTMX CytomX Therapeutics	2.42 of 5 stars	$2.77 +3.0%	$11.90 +329.6%	+31.8%	$603.58M	$76.20M	N/A	69
STTK Shattuck Labs	2.8433 of 5 stars	$5.88 -1.5%	$12.78 +117.3%	+166.1%	$590.12M	$1M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. ALT, VALN, CTMX, STTK, and ALLO

How does Molecular Partners compare to Altimmune?

Summary

How does Molecular Partners compare to Valneva?

Summary

How does Molecular Partners compare to CytomX Therapeutics?

Summary

How does Molecular Partners compare to Shattuck Labs?

Summary

How does Molecular Partners compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. ALT, VALN, CTMX, STTK, and ALLO

How does Molecular Partners compare to Altimmune?

Is MOLN or ALT more profitable?

Which has more volatility and risk, MOLN or ALT?

Do analysts rate MOLN or ALT?

Which has stronger valuation & earnings, MOLN or ALT?

Do institutionals and insiders have more ownership in MOLN or ALT?

Does the media refer more to MOLN or ALT?

Summary

How does Molecular Partners compare to Valneva?

Which has more volatility & risk, MOLN or VALN?

Which has higher earnings & valuation, MOLN or VALN?

Does the media refer more to MOLN or VALN?

Is MOLN or VALN more profitable?

Do insiders & institutionals hold more shares of MOLN or VALN?

Do analysts rate MOLN or VALN?

Summary

How does Molecular Partners compare to CytomX Therapeutics?

Is CTMX or MOLN more profitable?

Which has better valuation & earnings, CTMX or MOLN?

Do institutionals & insiders believe in CTMX or MOLN?

Which has more volatility & risk, CTMX or MOLN?

Do analysts prefer CTMX or MOLN?

Does the media prefer CTMX or MOLN?

Summary

How does Molecular Partners compare to Shattuck Labs?

Do institutionals and insiders have more ownership in STTK or MOLN?

Does the media prefer STTK or MOLN?

Which has more volatility and risk, STTK or MOLN?

Which has preferable earnings and valuation, STTK or MOLN?

Is STTK or MOLN more profitable?

Do analysts rate STTK or MOLN?

Summary

How does Molecular Partners compare to Allogene Therapeutics?

Do analysts prefer ALLO or MOLN?

Which has more volatility and risk, ALLO or MOLN?

Does the media prefer ALLO or MOLN?

Which has preferable valuation and earnings, ALLO or MOLN?

Do insiders & institutionals hold more shares of ALLO or MOLN?

Is ALLO or MOLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools